Envoy Medical

COCH · NASDAQ

$0.6345−$0.0195 (−2.98%)TodayMarket closed · Oct 20, 7:03 PM ET

Prev close $0.654

COCH analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $2.04 (+221.5% upside)

Low: $2.02
Now: $0.6345
High: $2.10

Upgrades and downgrades

The latest rating actions, newest first

COCH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Lake Street	Oct 6, 2026	Initiates	Buy	$2.50	36%
HC Wainwright & Co.	Aug 21, 2026	Maintains	Buy	$2.50 → $2.00	40%
LUCID CAPITAL MARKETS	Jul 27, 2026	Initiates	Buy	$2.00	25%
HC Wainwright & Co.	Jul 15, 2026	Maintains	Buy	$2.50	40%
HC Wainwright & Co.	Mar 31, 2026	Initiates	Buy	$2.50	40%

The case for and against

Updated Oct 16, 2026

Bull case

Envoy Medical is supported by a differentiated, first-of-its-kind fully implanted cochlear implant strategy that could expand adoption by removing external components, reducing stigma, and leveraging the ear’s natural anatomy. The investment case is strengthened by encouraging clinical progression: 12-month CNC word recognition in the first 10 Stage 1 participants improved to 53.2% from 39.2% at six months and 15.2% pre-implantation, with 9 of 10 showing a positive hearing response and no protocol-defined serious adverse events reported. Despite only $51K of 2Q26 revenue and a $7.3M net loss, the first of four PMA modules was submitted in June 2026 and the pivotal 56-patient trial is advancing toward 2Q27 topline data, supporting long-term upside if results continue to mature.

Bear case

Envoy Medical is under pressure from a fragile liquidity profile, with $19.7M in cash at the end of June 2026 and ($5.5M) of operating cash burn in 2Q26, suggesting it may need additional capital within the next 12 months absent warrant exercises. The company’s reliance on the Esteem FI-AMEI for all substantial revenue leaves it highly exposed to a narrow commercial base, while the Acclaim CI remains investigational and subject to clinical, regulatory, and adoption risk. Compounding these concerns, the company faces NASDAQ minimum bid-price compliance by November 16, 2026 and meaningful dilution risk from up to $48M of gross proceeds tied to outstanding Series A-1 and Series A-2 warrants.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.